Is this message not displayed correctly?
Please click here for the online version.

Dear , Welcome to the latest issue of the HealthCapital newsletter,

Berlin’s strength in life sciences has never been built on excellence alone. It has been built on the ability to connect outstanding science, clinical practice, and entrepreneurial ambition across a uniquely collaborative ecosystem. 

As global competition for talent, technologies, and investment intensifies, we are strengthening the infrastructures that turn Berlin’s scientific excellence into health innovations with global impact. Facilities such as Si-M – The Simulated Human and the Berlin Center for Advanced Therapies (BeCAT) strengthen our capacity to translate research into diagnostics, therapies, and real-world patient benefit. 

This ambition is reflected in the recently launched Deep Tech Berlin Agenda, which places technology transfer and innovation at the center of the city’s future growth. The launch of Si-M and BeCAT demonstrates how these goals are already becoming reality. 

Si-M is developing innovative human disease models that help researchers better understand complex diseases and improve therapeutic development. BeCAT provides the infrastructure required to advance novel cell and gene therapies and other advanced therapy approaches towards clinical application. Both facilities address critical bottlenecks in biomedical innovation and help bridge the gap between basic research and patient care. 

More than individual projects, Si-M and BeCAT serve as key nodes within Berlin’s life sciences ecosystem, connecting universities, research institutes, hospitals, companies, and investors. They illustrate how strategic investments in research infrastructure can foster collaboration, accelerate innovation, and translate scientific excellence into real-world impact. In this issue, we explore these two landmark facilities and examine why state-of-the-art research infrastructures have become essential assets in the global competition for talent, technologies, and biomedical innovation. 

The strength of Berlin’s life sciences ecosystem is also reflected in recent scientific achievements. New work by Prof. Leif Sander and his team at Charité on the treatment of a patient infected with the Bundibugyo Ebola virus, as well as findings on post-exposure prophylaxis, provides valuable insights for the management of highly dangerous infectious diseases. Together with recent funding for the development of a new Ebola vaccine by Minapharm and its Berlin-based subsidiary ProBioGen, these developments highlight how scientific excellence, clinical expertise, and advanced research infrastructure can work together to address global health challenges. 

With kind regards from Berlin
Dr. Kai Uwe Bindseil
Berlin Partner for Business and Technology